A5018891184- Cutaneous Melanoma Detection and Management
- Melanoma and MAPK Pathways
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Brain Metastases and Treatment
- Lung Cancer Research Studies
- Sarcoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Lung Cancer Treatments and Mutations
- Management of metastatic bone disease
- Glioma Diagnosis and Treatment
- Cell Image Analysis Techniques
- Testicular diseases and treatments
- Peptidase Inhibition and Analysis
- Nonmelanoma Skin Cancer Studies
- HER2/EGFR in Cancer Research
- Chronic Lymphocytic Leukemia Research
The Maria Sklodowska-Curie National Research Institute of Oncology
2014-2024
Centrum Onkologii
2019
Ipilimumab plus nivolumab (COMBO) is the standard treatment in asymptomatic patients with melanoma brain metastases (MBM). We report a retrospective study aiming to assess outcome of MBM treated COMBO outside clinical trials.
9518 Background: Pts with resected AJCC v8 stage IIIA melanoma have been under-represented in clinical trials of adjuvant drug therapy. The benefit targeted and immunotherapy this population is unclear. Methods: In multicenter, retrospective study, pts (AJCC v8) who received pembrolizumab or nivolumab (PD1), BRAF/MEK-targeted therapy dabrafenib + trametinib (TT), no treatment (OBS) were included. Recurrence free survival (RFS), distant metastasis (DMFS), toxicity rates examined. Results: 613...
Abstract Background Patients with Ewing sarcoma (EWS) who develop refractory or relapsed disease have limited treatment options. In some centres in Europe the combination of etoposide carbo‐ cisplatin is being used for these patients, however, there are no published data available yet. Here we investigated outcome patients advanced progression after standard treatment. Procedure All diagnosed EWS between 1980 and 2012 one six major treated either carboplatin were included retrospectively...
The landscape of melanoma management changed as randomized trials have launched adjuvant treatment.An analysis data on 248 consecutive stage III and IV patients given therapy in eight centers (February 2019 to January 2021) was conducted.The analyzed cohort comprised 147 anti-PD1 (33% nivolumab, 26% pembrolizumab), 101 (41%) were dabrafenib plus trametinib (DT). 2-year overall survival (OS), relapse-free (RFS), distant-metastases-free (DMFS) rates 86.7%, 61.4%, 70.2%, respectively. disease...
Stage IV melanoma patients develop brain metastases (MBM) in 50% of cases. Their prognosis is improving, and its understanding outside the context clinical trials relevant. We have retrospectively analyzed data, course treatment, outcomes 531 subsequent stage with BM treated five reference Italian Polish centers between 2014 2021. Patients MBM after 2017 had a better prognosis, significantly improved median overall survival (OS) worst mol-GPA prognostic groups (mol-GPA ≤ 2): OS >6 months...
9575 Background: Both anti-PD-1 antibodies and BRAK/MEK inhibitors (BRAF/MEKi) reduce the risk of recurrence for patients with resected stage III melanoma. For V600 BRAF-mutated melanoma who recur resectable disease on or after adjuvant, many may be suitable ‘second adjuvant' treatment surgery. We sought to examine efficacy safety adjuvant’ BRAF/MEKi in recurred despite adjuvant PD-1 based immunotherapy. Methods: Patients treated immunotherapy III/IV recurred, underwent resection were then...
Ewing sarcoma is a rare malignant neoplasm that primarily affects bone in children. Extraskeletal location less common, while intradural extramedullary (IEES) adults casuistic phenomenon. Due to its rarity, standardized treatment strategy for IEES has not been established. The clinical use of proton beam therapy (PBT) craniospinal irradiation (CSI) the reported literature. A 41-year-old previously healthy man presented with disabling gluteal and lower extremity pain, decreased sensation,...
e21541 Background: Immunotherapy (ITH) holds the possibility of tumor burden decrease after initial RECIST defined progression (PD). Clinical concept treating selected patients (pts) beyond PD is supported by this pseudoprogression phenomenon. The aim study was to evaluate real-life practice and outcomes related treatment (TBP) in melanoma patients. Methods: We evaluated advanced pts who started anti-PD1 between 12/2015 12/2018 identified received TBP had subsequent imaging burden. Survival...
9575 Background: Despite improved outcomes with the use of adjuvant PD1 therapy, approximately 50% patients (pts) develop recurrent disease by 5 years. Data to define best management recurrences is lacking, including whether retreatment has benefit. Methods: This was a multicentre, international retrospective study pts resected stage II-IV melanoma who commenced therapy before January 2022 and then recurred. Demographics, characteristics, treatment, toxicity, recurrence patterns, were...
Nowe terapie stosowane w leczeniu chorych na czerniaka wydłużyły czas przeżycia i wpłynęły poprawę jakości ich życia. Przedstawiono przypadek chorej, u której wykonanym rezonansie magnetycznym potwierdzono obecność pojedynczego ogniska przerzutowego prawym płacie czołowym przebiegu leczenia pembrolizumabem utrzymującej się odpowiedzi leczenie we wcześniej zajętych chorobą narządach. Równolegle z radioterapią stereotaktyczną pacjentka otrzymywała pembrolizumab, który następnie kontynuowano....